Daily Endocrinology Research Analysis
Three impactful endocrinology papers stood out: a preclinical gene-editing study restored adrenal 21-hydroxylase function in a CAH mouse model with durable effects; a multicenter pediatric RCT of inhaled technosphere insulin did not meet HbA1c noninferiority but showed safety, higher treatment satisfaction, and less weight gain; and a nationwide Korean cohort produced a 13-variable nomogram predicting ESRD in type 2 diabetes with excellent discrimination.
Summary
Three impactful endocrinology papers stood out: a preclinical gene-editing study restored adrenal 21-hydroxylase function in a CAH mouse model with durable effects; a multicenter pediatric RCT of inhaled technosphere insulin did not meet HbA1c noninferiority but showed safety, higher treatment satisfaction, and less weight gain; and a nationwide Korean cohort produced a 13-variable nomogram predicting ESRD in type 2 diabetes with excellent discrimination.
Research Themes
- Gene editing therapies for endocrine disorders
- Pediatric diabetes therapeutics and delivery innovation
- Risk prediction and nephroprotection in type 2 diabetes
Selected Articles
1. Targeted editing of the 21-hydroxylase locus confers durable therapeutic effect in a murine model of congenital adrenal hyperplasia.
Dual-AAV, homology-independent targeted integration restored adrenal Cyp21a2 expression in a CAH mouse model, increasing corticosteroid production and reducing hyperplasia and renin/aldosterone synthase expression. Therapeutic effects persisted to 15 weeks—beyond adrenocortical turnover—suggesting progenitor targeting and durable correction. The strategy could cover most classical CAH mutations, supporting translational development.
Impact: Demonstrates durable, adrenal-targeted genomic correction in vivo, addressing a key limitation of gene addition in a renewing tissue. Establishes a therapeutic paradigm for CAH with strong translational potential.
Clinical Implications: If translated, this approach could reduce reliance on lifelong glucocorticoid/mineralocorticoid replacement, mitigate adrenal hyperplasia, and improve cardiometabolic outcomes by restoring physiologic steroidogenesis.
Key Findings
- Homology-independent targeted integration via dual AAV reconstituted adrenal 21-hydroxylase expression in vivo.
- Corticosteroid production increased while adrenal hyperplasia, renin, and aldosterone synthase expression decreased.
- Therapeutic effects persisted to 15 weeks, exceeding adrenocortical turnover, implying progenitor cell targeting and durability.
Methodological Strengths
- In vivo disease-model validation with hormonal, histological, and gene-expression endpoints.
- Durability assessment beyond expected adrenocortical turnover suggesting progenitor targeting.
Limitations
- Preclinical mouse model; human translation requires demonstration of safety, efficiency, and targeting in human adrenocortical progenitors.
- Off-target editing profile and long-term safety beyond 15 weeks were not detailed.
Future Directions: Optimize delivery and editing efficiency in large-animal models, perform comprehensive off-target/safety profiling, and develop clinical-grade vectors targeting human adrenocortical progenitors for first-in-human studies.
Contemporary treatment for congenital adrenal hyperplasia is lifesaving; however, long-term deleterious effects from the disease and complications from the inadequacy of available treatment remain problematic. Locus-specific correction of the defective 21-hydroxylase gene through genomic editing has the potential to address this unmet need by simultaneously restoring gene function and physiological control. Editing is necessitated by the constant cellular turnover in the adrenal cortex which limits the durability of conventional gene addition strategies using recombinant adeno-associated virus. We have developed a homology-independent targeted integration genomic editing strategy that conferred phenotypic benefit in a mouse model using a dual recombinant adeno-associated virus approach. Reconstitution of 21-hydroxylase expression in the adrenal gland increased corticosteroid production, reduced adrenal gland hyperplasia, and reduced expression of renin and aldosterone synthase with these effects maintained to 15 weeks without diminution. This is beyond the adrenocortical cellular turnover time, providing initial evidence of adrenocortical progenitor cell targeting. Importantly, the editing strategy used is potentially applicable to the majority of causative mutations in classical congenital adrenal hyperplasia. Collectively these data provide strong impetus for addressing the challenges of clinical translation, with development and evaluation of strategies for efficient targeting of human adrenocortical progenitor cells being the most formidable.
2. INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes.
In a 26-week multicenter RCT of 230 youth with predominantly type 1 diabetes, inhaled technosphere insulin did not meet noninferiority versus rapid-acting analogs for HbA1c. Time-in-range and pulmonary function were similar, while severe hypoglycemia was rare in both groups. TI improved treatment satisfaction and attenuated weight/BMI percentile gain.
Impact: Provides the first robust randomized evidence in children on inhaled insulin’s efficacy-safety balance, highlighting strengths (satisfaction, weight) and trade-offs (HbA1c).
Clinical Implications: TI can be considered for selected pediatric T1D patients prioritizing prandial flexibility, reduced weight gain, and device preferences, with counseling that HbA1c may not improve versus RAA. Ongoing monitoring of hypoglycemia and lung function remains prudent.
Key Findings
- Primary endpoint: HbA1c noninferiority versus RAA not met (adjusted difference 0.18%; 95% CI -0.07, 0.43; noninferiority P=0.091).
- No significant differences in CGM time-in-range or pulmonary function; severe hypoglycemia events were rare in both groups.
- TI increased treatment satisfaction (P=0.004) and reduced weight and BMI percentile gain (P=0.009) compared with RAA.
Methodological Strengths
- Multicenter randomized design with CGM-based outcomes and predefined noninferiority margin.
- Comprehensive safety assessment including pulmonary function and severe hypoglycemia.
Limitations
- Did not meet noninferiority for HbA1c; trial duration limited to 26 weeks.
- Predominantly type 1 diabetes population; generalizability to type 2 diabetes in youth is limited.
Future Directions: Longer trials to assess durability, dosing optimization, integration with hybrid closed-loop systems, and subgroup analyses (e.g., high baseline BMI) to clarify who benefits most.
OBJECTIVE: To evaluate inhaled technosphere insulin (TI) in children with diabetes. RESEARCH DESIGN AND METHODS: 230 youth 4-17 years old with type 1 (98%) or type 2 (2%) diabetes treated with multiple daily injections of insulin were randomly assigned 1:1 to TI or rapid-acting analog (RAA) insulin plus continuation of long-acting basal insulin and continuous glucose monitoring (CGM) for 26 weeks. The primary outcome was change in HbA1c, tested for noninferiority with margin of 0.4%. RESULTS: In intent-to-treat analysis, mean HbA1c (% ± SD) was 8.22 ± 0.87 at baseline and 8.41 ± 1.38 at 26 weeks with TI and 8.21 ± 0.96 and 8.21 ± 1.10, respectively, with RAA (adjusted difference = 0.18; 95% CI -0.07, 0.43; noninferiority P = 0.091). CGM-measured time in range 70-180 mg/dL was not significantly different between groups (adjusted difference -2.2%; 95% CI -7.0, 2.7; P = 0.38). Two severe hypoglycemic events occurred in the TI group and one in the RAA group. Change in forced expiration volume in 1 s from baseline to 26 weeks did not differ comparing TI and RAA (P = 0.53). The TI group reported greater treatment satisfaction (P = 0.004) and had less gain in weight and BMI percentile (P = 0.009) than did the RAA group. CONCLUSIONS: The primary analysis did not meet the prespecified criteria for HbA1c noninferiority. However, TI use was safe over 26 weeks without affecting pulmonary function and was associated with greater treatment satisfaction and less weight gain compared with RAA, supporting TI as a treatment option for some pediatric patients with type 1 diabetes.
3. A Nomogram for End-Stage Renal Disease Prediction in Patients with Type 2 Diabetes Mellitus: A Nationwide Cohort Study in Korea.
Using >2.4 million patients from Korea’s national database, investigators built and externally validated a 13-variable nomogram predicting ESRD in type 2 diabetes with excellent discrimination (C-index 0.906). Key predictors included demographics, lifestyle, CKD status, LDL ≥160 mg/dL, insulin use, and diabetes duration.
Impact: Delivers a pragmatic, validated risk tool at population scale to triage T2DM patients for renoprotective interventions and specialist referral.
Clinical Implications: Supports early nephrology referral and intensified use of SGLT2 inhibitors, finerenone, and LDL-lowering in high-risk T2DM identified by the nomogram; enables EHR integration for proactive kidney health management.
Key Findings
- Developed and validated a 13-variable ESRD risk nomogram in T2DM using national cohorts (development n=1,744,277; validation n=747,407).
- Validation performance was excellent (C-index 0.906; 95% CI 0.900–0.912).
- Predictors included male sex, smoking, physical inactivity, low income, low BMI, hypertension, LDL ≥160 mg/dL, CKD, insulin use, and longer diabetes duration.
Methodological Strengths
- Very large, nationwide cohorts with separate development and validation.
- Transparent Cox-based model with strong discrimination and clinically interpretable predictors.
Limitations
- Reliance on administrative codes and limited phenotyping; potential residual confounding.
- Generalizability outside Korea and across diverse ethnicities requires external validation.
Future Directions: Prospective impact studies to test clinical utility, integration into EHRs with CDS, and validation/adaptation across multi-ethnic populations.
BACKGROUND: Despite the rising incidence of end-stage renal disease (ESRD) among individuals with type 2 diabetes mellitus (T2DM) in Korea, no predictive model or nomogram has been developed using a nationwide cohort. In this study, we developed a nomogram to predict the long-term risk of ESRD in patients with T2DM using a large-scale, population-based Korean database. METHODS: Using the Korean National Health Insurance Database, patients with T2DM who underwent health examinations between 2015 and 2016 were assigned as development (n=1,744,277) and validation (n=747,407) cohorts. New ESRD cases were identified using codes for renal replacement therapy. A Cox proportional hazards regression model was used to derive a risk-scoring system, and 13 variables were selected. A risk score nomogram was then created to estimate the risk of ESRD. RESULTS: In the development cohort, 8,631 patients with T2DM developed ESRD during a follow-up period of 4.8±0.9 years. After multivariable adjustment, significant predictors of ESRD included male sex, current smoking, physical inactivity, low income, low body mass index, hypertension, low-density lipoprotein cholesterol ≥160 mg/dL, chronic kidney disease, insulin use, and longer duration of T2DM. A final nomogram incorporating 13 variables was developed to estimate the individual probability of ESRD. The concordance index for ESRD prediction in the validation cohort was 0.906 (95% confidence interval, 0.9 to 0.912). CONCLUSION: This 13-variable nomogram provides a simple tool for identifying patients with T2DM at high risk of ESRD and may aid in early intervention.